Abstract
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have